newsfilter
← Latest News
PR Newswire·

Lilly reports third-quarter 2026 financial results, raises full-year guidance and highlights regulatory progress across the portfolio

Revenue in Q3 2026 increased 39% to $24.4 billion driven primarily by Mounjaro and Zepbound. Q3 revenue included approximately $900 million of benefits, primarily from $410 million of Jardiance milestones (no further